Lung and pancreatic cancers are two of the most deadly cancers in the Western countries. They are characterized by a rapid progression and poor prognosis, with 5-year mortality rates over 85% and 95% respectively. Lung cancer is the most common worldwide diagnosed cancer and the major cause of mortality in the European Union with over 340,000 deaths per year. Pancreatic cancer is the fourth cause of mortality for malignant tumors in Europe with nearly 80,000 annual deaths. In spite of the knowledge gained in recent years on the underlying molecular mechanisms involved, these high mortality rates are a clear demonstration that current treatments are a failure and that there is an urgent need for improved clinical management.
The proposed consortium will foster interaction of basic researchers with a profound knowledge on the design of targeted and personalized cancer therapies, and clinical groups with an extensive experience in the management of lung and pancreatic cancer patients, guaranteeing a clinical proof-of principle and applicability, integrating basic-clinical European scientific excellence. In addition, industrial partners will contribute to the objectives of the consortium.